Overview

Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

Status:
Not yet recruiting
Trial end date:
2024-11-07
Target enrollment:
Participant gender:
Summary
This study aims to confirm the effectiveness of ezetimibe add-on therapy on LDL-C levels compared to atorvastatin monotherapy, especially in very high-risk patients. We intend to lay the foundation for a standard treatment for these patients through ezetimibe add on lipid-lowering therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Organon and Co
Collaborator:
Iqvia Pty Ltd
Treatments:
Atorvastatin